Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib with concurrent thoracic radiotherapy in advanced non-small cell lung cancer
ISRCTN92263269Phase 2Completed
- Sponsor
- Imperial College Healthcare NHS Trust
- Start
- Jan 2009
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Imperial College Healthcare NHS Trust. Primary endpoints: Maximum tolerated dose in combination with external beam radiotherapy and Disease control rate at 6 months. Started Jan 2009; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN92263269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN92263269.